The FDA’s weak drug manufacturing oversight is a potentially deadly problem: COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.

The FDA’s weak drug manufacturing oversight is a potentially deadly problem: COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.: https://ift.tt/3zQXVMX Read more... https://ift.tt/3eVAJ7h